Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 319

The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.

EAACI Guidelines on Allergen Immunotherapy: House dust mite‐driven allergic asthma

Open access
Agache, Ioana, Lau, Susanne, Akdis, Cezmi A., Smolinska, Sylwia, Bonini, Matteo, Cavkaytar, Ozlem, Flood, Breda, Gajdanowicz, Pawe, Izuhara, Kenji, Kalayci, Omer, Mosges, Ralph, Palomares, Oscar, Papadopoulos, Nikolaos G., Sokolowska, Milena, Angier, Elisabeth, Fernandez‐Rivas, Montserrat, Pajno, Giovanni, Pfaar, Oliver, Roberts, Graham C., Ryan, Dermot, Sturm, Gunter J., van Ree, Ronald, Varga, Eva M., van Wijk, Roy Gerth, Yepes‐Nuñez, Juan José, Jutel, Marek·2019·Allergy

Abstract

Allergen immunotherapy (AIT) has been in use for the treatment of allergic disease for more than 100 years. Asthma treatment relies mainly on corticosteroids and other controllers recommended to achieve and maintain asthma control, prevent exacerbations, and improve quality of life. AIT is underused in asthma, both in children and in adults. Notably, patients with allergic asthma not adequately controlled on pharmacotherapy (including biologics) represent an unmet health need. The European Academy of Allergy and Clinical Immunology has developed a clinical practice guideline providing evidence‐based recommendations for the use of house dust mites (HDM) AIT as add‐on treatment for HDM‐driven allergic asthma. This guideline was developed by a multi‐disciplinary working group using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. HDM AIT was separately evaluated by route of administration and children and adults: subcutaneous (SCIT) and sublingual AIT (SLIT), drops, and tablets. Recommendations were formulated for each. The important prerequisites for successful treatment with HDM AIT are (a) selection of patients most likely to respond to AIT and (b) use of allergen extracts and desensitization protocols of proven efficacy. To date, only AIT with HDM SLIT‐tablet has demonstrated a robust effect in adults for critical end points (exacerbations, asthma control, and safety). Thus, it is recommended as an add‐on to regular asthma therapy for adults with controlled or partially controlled HDM‐driven allergic asthma (conditional recommendation, moderate‐quality evidence). HDM SCIT is recommended for adults and children, and SLIT drops are recommended for children with controlled HDM‐driven allergic asthma as the add‐on to regular asthma therapy to decrease symptoms and medication needs (conditional recommendation, low‐quality evidence).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/all.13749

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 94 references

Cited by

See all 319

Metadata

Authors
Agache, I., Lau, S., Akdis, C. A., Smolinska, S., Bonini, M., Cavkaytar, O., Flood, B., Gajdanowicz, P., Izuhara, K., Kalayci, O., Mosges, R., Palomares, O., Papadopoulos, N. G., Sokolowska, M., Angier, E., Fernandez‐Rivas, M., Pajno, G., Pfaar, O., Roberts, G. C., Ryan, D., Sturm, G. J., van Ree, R., Varga, E. M., van Wijk, R. G., Yepes‐Nuñez, J. J., & Jutel, M.
Venue
Allergy
Publisher
Wiley
Published
2019-05
Volume
74
Issue
5
Pages
855-873
ISSN
  • 0105-4538 (ISSN-L)
  • 1398-9995
OpenAlex
W2945085089
Cited by
319
References
94
FWCI
23.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EAACI Guidelines on Allergen Immunotherapy: House dust mite‐driven allergic asthma. https://app.cochat.ai/papers/10.1111/all.13749
The paper
Agache, I., Lau, S., Akdis, C. A., Smolinska, S., Bonini, M., Cavkaytar, O., Flood, B., Gajdanowicz, P., Izuhara, K., Kalayci, O., Mosges, R., Palomares, O., Papadopoulos, N. G., Sokolowska, M., Angier, E., Fernandez‐Rivas, M., Pajno, G., Pfaar, O., Roberts, G. C., . . . Jutel, M. (2019). EAACI Guidelines on Allergen Immunotherapy: House dust mite‐driven allergic asthma. Allergy. https://doi.org/10.1111/all.13749

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.